Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Humboldt Research Award for Nobel Laureate Aaron Ciechanover - Host Institution is the MDC

07.12.2011
The Israeli Nobel Laureate Aaron Ciechanover has been named one of the recipients of the Humboldt Research Award of the Alexander von Humboldt Foundation (AvH). His host institution in Germany shall be the Max Delbrück Center (MDC) in Berlin, a member of the Helmholtz Association.

Professor Ciechanover is a physician and biologist and conducts research at the Technion – Israel Institute of Technology in Haifa. AvH in Germany awards this prize to internationally renowned scientists and scholars in recognition of their entire achievements to date, and whose fundamental discoveries, theories, or insights have had a significant impact on their discipline. The award is valued at 60,000 euros.

At the MDC Professor Ciechanover will cooperate in particular with the research group led by Professor Thomas Sommer. There he will work in joint projects on the disposal of misfolded proteins. This cooperation will enable the MDC to intensify its contacts with Israeli scientists and in particular with the Technion.

Professor Ciechanover is one of the discoverers of the ubiquitin-proteasome system for regulated protein degradation. One of the main functions of the system is waste disposal. In 2004 he shared the Nobel Prize in Chemistry for this discovery with Avram Hershko and Irwin Rose. This quality control maintenance system selectively disposes misfolded/denatured/inactive proteins that, if accumulated, can cause cellular damage. Thus, only proteins that are marked with ubiquitin are recognized and enter the proteasome, the molecular shredder of the cell. There they are chopped into pieces and degraded. Ubiquitin, as the name (ubiquitous) implies, is present in all eukaryotic (nucleated) cells.

Aberrations in this cellular waste disposal machinery can lead to a wide array of diseases, ranging from cancer to neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease, genetic diseases such as cystic fibrosis, and disorders of the immune system. The research on the ubiquitin-proteasome system and the identification of the components involved in the degradation of key proteins has already led to the development of a new cancer drug. Aaron Ciechanover is convinced that this research will lead to the development of many additional drugs that will selectively target only proteins that are involved in a specific disease process.

Aaron Ciechanover was born in Haifa, Israel in 1947. He received his MD degree from Hebrew University of Jerusalem in 1975, and his PhD in Biology from Technion in 1982. He is currently Distinguished Professor at the Cancer and Vascular Biology Research Center in the Rappaport Research Institute and Faculty of Medicine, Technion – Israel Institute of Technology. Prior to receiving the Nobel Prize he was a recipient of the 2000 Albert Lasker Award and the 2003 Israel Prize. He is a member of the Israeli Academy of Sciences and Humanities, and the National Academy of Sciences of the USA (Foreign Member).

Barbara Bachtler
Press Department
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
in the Helmholtz Association
Robert-Rössle-Straße 10
13125 Berlin
Phone: +49 (0) 30 94 06 - 38 96
Fax: +49 (0) 30 94 06 - 38 33
e-mail: presse@mdc-berlin.de

Barbara Bachtler | Max-Delbrück-Centrum
Further information:
http://www.technioncancer.co.il/ResearchGroups.php
http://www.mdc-berlin.de/

More articles from Awards Funding:

nachricht Hellmuth Fischer Medal – Call for Nominations
22.07.2014 | DECHEMA Gesellschaft für Chemische Technik und Biotechnologie e.V.

nachricht German Government Supports Advancement of Clean and Efficient Fuel Cells with €4.9 Mio
22.07.2014 | Fraunhofer-Institut für Keramische Technologien und Systeme IKTS

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

“Lens on Life” - Artists and Scientists Explore Cell Divison

08.07.2014 | Event News

First International Conference on Consumer Research | ICCR 2014: Early bird deadline July 31, 2014

08.07.2014 | Event News

First evidence for painless atrial fibrillation treatment

04.07.2014 | Event News

 
Latest News

Siemens installs two offshore platforms for TenneT in the North Sea in July

22.07.2014 | Press release

Hubble traces the halo of a galaxy more accurately than ever before

22.07.2014 | Physics and Astronomy

Quantum leap in lasers at Dartmouth brightens future for quantum computing

22.07.2014 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>